несмотря на приём АНЛ, глюкоза в крови на нижней границе нормы.

Там глюкозу измеряли в ликворе и прием АНЛ уровень глюкозы как раз уменьшает(в статье Сабины Бан написано), что у Вас и наблюдается.

Да щас же! В ряде случаев АНЛ вообще провоцируют развитие сахарного диабета II типа

As described in their research paper "Synchronous neural interactions assessed by magnetoencephalography: a functional biomarker for brain disorders", the team demonstrated that interactions among neuronal populations - an essential aspect of brain function - can potentially act as biomarkers for several brain diseases.

... We found that subsets of z(ij)(0) successfully classified individual subjects to their respective groups (multiple sclerosis, Alzheimer's disease, schizophrenia, Sjögren's syndrome, chronic alcoholism, facial pain, healthy controls) and gave excellent external cross-validation results.

Повышение уровней альфа-дефензинов в крови как маркер предрасположенности к шизофрении". Журнал молекулярной и клеточной протеомики. Кембриджская группа Сабины Бан. Даже почтовый адрес Сабины приложен. И Фуллер Торри в соавторах. (0:

Increased alpha defensins as a blood marker for schizophrenia susceptibility
Rachel M. Craddock, Jeffrey T. Huang, Edmund Jackson, Nathan Harris, E. Fuller Torrey, Marlis Herberth, and Sabine Bahn
Institute of Biotechnology, University of Cambridge, Cambridge CB2 1Q
Corresponding Author: sb209@cam.ac.uk

Это всего лишь одна неожиданная находка

Schizophrenia is associated with alterations of the immune system. There are, however, only limited data dealing with immune parameters in unmedicated schizophrenic patients and the course of these parameters during treatment. In this study, we monitored CD19+ (B)- and CD3+ (T)-lymphocytes in the course of antipsychotic treatment. Forty patients diagnosed with an acute exacerbation of schizophrenia were tested before and after 3 days, 2 weeks, 4 weeks and 3 months of treatment with antipsychotics. The percentages of CD19+- and CD3+-lymphocytes were analysed by flow cytometry using fluorescence conjugated anti-CD19 and anti-CD3 antibodies. Twenty healthy volunteers served as controls. In the acute state of psychosis, a significant reduction of the CD3+-lymphocyte subpopulation was observed, while the percentage of CD19+-lymphocytes was increased. Both subpopulations levelled to those of the control group in the course of treatment. As expected, the levels of the immune parameters did not change in the healthy controls during the course of the study. The observed alterations of the CD19+- and CD3+-lymphocytes in the acute state of psychosis especially in patients with the paranoid subtype of schizophrenia, and the “normalization” during the observation period are discussed under the aspect of the immune hypothesis of schizophrenia, in particular of the type-1/type-2 imbalance hypothesis.

AUSTIN, TX (June 11, 2008) – Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory, announced today that it is partnering with Psynova Neurotech to co-develop and commercialize a blood test for the diagnosis of schizophrenia. RBM and Psynova will focus on the unmet clinical need for an objective and reliable diagnostic test to accelerate and optimize the treatment of schizophrenia. Under the terms of the agreement, the companies will collaborate on the validation, regulatory approval and manufacture of a diagnostic blood test for schizophrenia that will be sold worldwide exclusively by RBM.

The co-development agreement will leverage Psynova’s discovery of proprietary biomarkers with RBM’s protein biomarker platform and CLIA-certified central lab service to accelerate the delivery of an objective diagnostic blood test for schizophrenia. These biomarkers were discovered through Psynova’s collaborative research program with co-founder Dr. Sabine Bahn of the Cambridge Centre for Neuropsychiatric Research (CCNR) at the Institute of Biotechnology, Cambridge University. The Psynova/CCNR research program included the processing of clinical samples on RBM’s HumanMAP®, which features over 150 quantitative immunoassays.

“This is a very exciting and important partnership for Psynova,” said Dr. Sabine Bahn, director and co-founder of Psynova Neurotech. “RBM’s technology platform and clinical screening expertise give us a rapid path to bring the candidate biomarkers identified through our research efforts to the benefit of patients. The tests will be a tool to help general practitioners and psychiatrists in the difficult task of diagnosing and treating patients much sooner, ideally, when symptoms are still mild. The Psynova biomarkers not only have the potential to help in the identification of disease subtypes, but also in deciding the best treatment options, monitoring patient responses and facilitating novel approaches to drug discovery.”

The current diagnosis of schizophrenia is highly subjective and time-consuming, due to the lack of objective biological tests specific for the disease. The resulting uncertainty in diagnosis leads to delayed treatment, and, in turn, extended suffering and hardship for patients and their families. In the few studies where early treatment has been implemented in high-risk patient groups, poor outcomes were substantially reduced, as were the duration of untreated illness, inpatient days and the time to remission. Therefore, a test that provides earlier and more accurate diagnosis of the disease would deliver not only improved patient outcomes but also greatly reduce the overall costs of schizophrenia to health services and society.1 “Complex diseases like schizophrenia are an ideal fit for RBM’s multiplex testing approach,” said RBM CEO T. Craig Benson. “By combining RBM’s expertise in assay development and testing services with Psynova Neurotech’s proprietary biomarkers, we can improve the standard of care for schizophrenia, ultimately providing significant savings to health care systems worldwide. We anticipate that this is the first of many collaborations between the two companies, further leveraging other discoveries made by Psynova and the Cambridge Centre for Neuropsychiatric Research.”

The Global Alliance of Mental Illness Advocacy Networks - Europe (GAMIAN- Europe), a pan-European patient-driven federation of national organizations assisting people affected by mental illness, also welcomed the announcement.

“Any diagnostic tool that aids in the early identification of schizophrenia and other chronic mental illnesses will help people begin treatment earlier to avoid much of the pain, hardship and deterioration caused by these devastating diseases,” said Dolores Gauci, president of GAMIAN - Europe. “Further, such a test could help affected individuals and their carers maintain a better quality of life.”

Аутизм, мне кажется, может оказаться еще посложнее шизофрении по механизмам, во всяком случае, разнообразнее..